Progenics Pharmaceuticals, Inc. (PGNX) Holdings Boosted by Metropolitan Life Insurance Co. NY
Metropolitan Life Insurance Co. NY raised its holdings in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 414.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,521 shares of the biotechnology company’s stock after purchasing an additional 22,171 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Progenics Pharmaceuticals were worth $116,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in PGNX. Advisor Group Inc. increased its holdings in shares of Progenics Pharmaceuticals by 2,466.1% in the 4th quarter. Advisor Group Inc. now owns 12,651 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 12,158 shares during the last quarter. Pacer Advisors Inc. bought a new stake in shares of Progenics Pharmaceuticals in the 3rd quarter valued at approximately $102,000. Fosun International Ltd increased its holdings in shares of Progenics Pharmaceuticals by 14.0% in the 4th quarter. Fosun International Ltd now owns 454,588 shares of the biotechnology company’s stock valued at $1,773,000 after acquiring an additional 56,000 shares during the last quarter. Teachers Advisors LLC increased its holdings in shares of Progenics Pharmaceuticals by 6.9% in the 3rd quarter. Teachers Advisors LLC now owns 241,655 shares of the biotechnology company’s stock valued at $1,515,000 after acquiring an additional 15,696 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Progenics Pharmaceuticals by 9.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,160,542 shares of the biotechnology company’s stock valued at $7,277,000 after acquiring an additional 97,561 shares during the last quarter. 87.59% of the stock is currently owned by institutional investors.
A number of brokerages have recently weighed in on PGNX. Zacks Investment Research upgraded Progenics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a report on Thursday, February 21st. BidaskClub upgraded Progenics Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, April 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Progenics Pharmaceuticals has an average rating of “Buy” and an average price target of $10.35.
Progenics Pharmaceuticals (NASDAQ:PGNX) last issued its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.14). The company had revenue of $3.24 million for the quarter, compared to the consensus estimate of $10.99 million. Progenics Pharmaceuticals had a negative return on equity of 59.85% and a negative net margin of 433.09%. On average, equities analysts forecast that Progenics Pharmaceuticals, Inc. will post -0.62 earnings per share for the current fiscal year.
WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/progenics-pharmaceuticals-inc-pgnx-holdings-boosted-by-metropolitan-life-insurance-co-ny/2980708.html.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc, an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer.
Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.